Tumor endothelial cells express high pentraxin 3 levels. Issue 12 (14th November 2016)

• Record Type: Journal Article
• Authors: Hida, Kyoko; Maishi, Nako; Kawamoto, Taisuke; Akiyama, Kosuke; Ohga, Noritaka; Hida, Yasuhiro; Yamada, Kenji; Hojo, Takayuki; Kikuchi, Hiroshi; Sato, Masumi; Torii, Chisaho; Shinohara, Nobuo; Shindoh, Masanobu
• Is Part Of: Pathology international. Volume 66:Issue 12(2016)
• Page Start: 687
• Page End: 694
• Publication Date: 2016-11-14
• Subjects: angiogenesis -- antiangiogenic drugs -- cancer -- pentraxin 3 -- tumor endothelial cells; Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12474
• Languages: English
• ISSNs: 1320-5463

Abstract

Abstract : It has been described that tumor progression has many similarities to inflammation and wound healing in terms of the signaling processes involved. Among biological responses, angiogenesis, which is necessary for tumor progression and metastasis, is a common hallmark; therefore, tumor blood vessels have been considered as important therapeutic targets in anticancer therapy. We focused on pentraxin 3 (PTX3), which is a marker of cancer‐related inflammation, but we found no reports on its expression and function in tumor blood vessels. Here we showed that PTX3 is expressed in mouse and human tumor blood vessels based on immunohistochemical analysis. We found that PTX3 is upregulated in primary mouse and human tumor endothelial cells compared to normal endothelial cells. We also showed that PTX3 plays an important role in the proliferation of the tumor endothelial cells. These results suggest that PTX3 is an important target for antiangiogenic therapy.